India, June 30 -- Shares of Vistagen Therapeutics Inc. (VTGN) are down over 70% on Tuesday, following disappointing results from its PALISADE-4 trial.
PALISADE-4 was a U.S. multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical trial that evaluated the efficacy, safety, and tolerability of a single dose of Fasedienol in reducing anxiety symptoms in adults with social anxiety disorder during a simulated anxiety-provoking public speaking challenge with the Subjective Units of Distress Scale (SUDS) as the primary endpoint.
According to the trial results, Fasedienol did not achieve statistically significant improvement on primary and secondary endpoints. However, in a post-hoc analysis, Fasedienol achieved a nominal stati...